Anatara Lifesciences Financials
ANR Stock | 0.06 0 1.72% |
Operating Margin 2.846 | Return On Equity (1.27) |
Anatara | Select Account or Indicator |
Understanding current and past Anatara Lifesciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Anatara Lifesciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Anatara Lifesciences' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Anatara Lifesciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Anatara Lifesciences. Check Anatara Lifesciences' Beneish M Score to see the likelihood of Anatara Lifesciences' management manipulating its earnings.
Anatara Lifesciences Stock Summary
Anatara Lifesciences competes with Aurelia Metals, Pinnacle Investment, Data3, Auctus Alternative, and Dicker Data. Anatara Lifesciences is entity of Australia. It is traded as Stock on AU exchange.Foreign Associate | USA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | Australia Stock View All |
Exchange | Australian Securities Exchange |
ISIN | AU000000ANR0 |
Business Address | 81 Flinders Street, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | anataralifesciences.com |
Phone | 61 4 3802 7172 |
You should never invest in Anatara Lifesciences without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Anatara Stock, because this is throwing your money away. Analyzing the key information contained in Anatara Lifesciences' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Anatara Lifesciences Key Financial Ratios
Anatara Lifesciences' financial ratios allow both analysts and investors to convert raw data from Anatara Lifesciences' financial statements into concise, actionable information that can be used to evaluate the performance of Anatara Lifesciences over time and compare it to other companies across industries.Revenue | (123.18 K) | ||||
Gross Profit | (1.6 M) | ||||
EBITDA | (1.46 M) | ||||
Net Income | (1.45 M) | ||||
Total Asset | 1.67 M |
Anatara Lifesciences Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 3.3M | 4.3M | 1.8M | 1.4M | 1.7M | 1.6M | |
Cash | 2.7M | 3.4M | 1.1M | 351.2K | 982.1K | 933.0K | |
Net Receivables | 630.3K | 772.6K | 508.5K | 1.0M | 671.1K | 518.6K | |
Total Liab | 487.0K | 496.7K | 403.4K | 494.8K | 306.8K | 433.2K | |
Common Stock | 17.0M | 19.8M | 19.9M | 21.4M | 23.2M | 14.6M | |
Other Current Assets | 23.7K | 37.1K | 22.0K | 10.9K | 17.4K | 16.6K | |
Other Current Liab | 430.2K | 192.9K | 184.8K | 415.3K | 56.1K | 53.3K | |
Net Debt | (2.7M) | (3.4M) | (1.1M) | (351.2K) | (982.1K) | (1.0M) | |
Retained Earnings | (14.7M) | (16.6M) | (19.0M) | (20.8M) | (22.1M) | (21.0M) | |
Accounts Payable | 33.9K | 195.6K | 152.6K | 78.8K | 248.0K | 149.2K | |
Total Current Assets | 3.3M | 4.2M | 1.7M | 1.4M | 1.7M | 1.6M | |
Net Tangible Assets | 2.9M | 3.8M | 1.4M | 924.5K | 832.1K | 790.5K | |
Net Invested Capital | 2.9M | 3.8M | 1.4M | 924.5K | 1.4M | 1.3M | |
Net Working Capital | 2.9M | 3.8M | 1.3M | 921.9K | 1.4M | 1.3M | |
Other Liab | 22.9K | 28.3K | 81.0 | 665.0 | 598.5 | 568.57 | |
Capital Stock | 17.0M | 19.8M | 19.9M | 21.4M | 23.2M | 21.7M |
Anatara Lifesciences Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Research Development | 1.3M | 840.8K | 747.2K | 1.6M | 748.9K | 781.0K | |
Cost Of Revenue | 16.1K | 6.3K | 24.7K | 24.8K | 748.9K | 786.4K | |
Gross Profit | (16.1K) | (6.3K) | (24.7K) | (24.8K) | (748.9K) | (711.5K) | |
Operating Income | (4.2M) | (3.1M) | (3.0M) | (3.3M) | (1.5M) | (1.5M) | |
Ebit | (4.0M) | (3.0M) | (3.0M) | (3.2M) | (1.5M) | (1.5M) | |
Ebitda | (4.0M) | (3.0M) | (3.0M) | (3.2M) | (1.5M) | (1.5M) | |
Income Before Tax | (4.0M) | (3.0M) | (3.0M) | (3.2M) | (2.1M) | (2.2M) | |
Net Income | (3.4M) | (2.0M) | (2.5M) | (2.0M) | (1.5M) | (1.5M) | |
Income Tax Expense | (659.8K) | (1.0M) | (468.5K) | (1.2M) | (626.1K) | (657.4K) | |
Net Interest Income | 52.1K | 8.8K | 2.7K | 15.9K | 7.9K | 7.5K | |
Interest Income | 52.1K | 9.1K | 6.0K | 18.3K | 7.9K | 7.5K |
Anatara Lifesciences Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
End Period Cash Flow | 2.7M | 3.4M | 1.1M | 351.2K | 982.1K | 1.8M | |
Change In Cash | 1.3M | 749.7K | (2.3M) | (769.0K) | 630.9K | 662.5K | |
Free Cash Flow | (2.7M) | (2.1M) | (2.2M) | (2.3M) | (1.2M) | (1.3M) | |
Other Non Cash Items | 72.0K | 272.7K | (106.4K) | 442.9K | (170.4K) | (161.9K) | |
Net Income | (3.4M) | (2.0M) | (2.5M) | (2.0M) | (1.5M) | (1.5M) | |
Investments | 4.1M | (4.0K) | (50K) | (1.7K) | 50K | 52.5K | |
Depreciation | 16.1K | 6.3K | 24.7K | 24.8K | 2.5K | 2.3K | |
Change To Netincome | 305.5K | 117.9K | 74.8K | 70.9K | 63.8K | 60.6K | |
Change To Inventory | (931.9K) | 732.8K | 64.1K | (165.2K) | (190.0K) | (180.5K) |
Anatara Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Anatara Lifesciences's current stock value. Our valuation model uses many indicators to compare Anatara Lifesciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Anatara Lifesciences competition to find correlations between indicators driving Anatara Lifesciences's intrinsic value. More Info.Anatara Lifesciences is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Anatara Lifesciences' earnings, one of the primary drivers of an investment's value.Anatara Lifesciences Systematic Risk
Anatara Lifesciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Anatara Lifesciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Anatara Lifesciences correlated with the market. If Beta is less than 0 Anatara Lifesciences generally moves in the opposite direction as compared to the market. If Anatara Lifesciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Anatara Lifesciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Anatara Lifesciences is generally in the same direction as the market. If Beta > 1 Anatara Lifesciences moves generally in the same direction as, but more than the movement of the benchmark.
Anatara Lifesciences Total Assets Over Time
Anatara Lifesciences November 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Anatara Lifesciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Anatara Lifesciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Anatara Lifesciences based on widely used predictive technical indicators. In general, we focus on analyzing Anatara Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Anatara Lifesciences's daily price indicators and compare them against related drivers.
Downside Deviation | 6.63 | |||
Information Ratio | 0.0697 | |||
Maximum Drawdown | 36.06 | |||
Value At Risk | (8.93) | |||
Potential Upside | 7.69 |
Additional Tools for Anatara Stock Analysis
When running Anatara Lifesciences' price analysis, check to measure Anatara Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anatara Lifesciences is operating at the current time. Most of Anatara Lifesciences' value examination focuses on studying past and present price action to predict the probability of Anatara Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anatara Lifesciences' price. Additionally, you may evaluate how the addition of Anatara Lifesciences to your portfolios can decrease your overall portfolio volatility.